Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36159 | 0.96 | CYP2C9 (0.44) | CYP2C9EPHX2HSD11B1KDM4ETDP1 | |
| SCHEMBL28251936 | 0.93 | CYP2C9 (0.42) | CYP2C9EPHX2HSD11B1KDM4ETDP1 | |
| SCHEMBL28251937 | 0.93 | CYP2C9 (0.42) | CYP2C9EPHX2HSD11B1KDM4ETDP1 | |
| SCHEMBL11700359 | 0.76 | — | — | |
| SCHEMBL12765525 | 0.76 | CYP2C9 (0.35) | CYP2C9 | |
| SCHEMBL9427059 | 0.73 | CYP2C9 (0.32) | CYP2C9 | |
| SCHEMBL28325829 | 0.73 | CYP2C9 (0.32) | CYP2C9 | |
| Methacrylic Acid SCHEMBL2965962 | 0.72 | HSD11B1 (0.39) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL24843655 | 0.71 | — | — | |
| SCHEMBL12684913 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105308058-B | Metal complexes comprising tridentate aminocarbene ligands and hydrogenation reduction methods using the same | 株式会社可乐丽 | 2018-10-12 | — | — | CN | disclosed |
| US-6770777-B2 | REACTING 2-ADAMANTANONE AND ALKYL HALIDE WITH LITHIUM; SALT FORMATION OF LITHIUM 2-ALKYL-2- ADAMANTYL ALCOHOLATE; REACTING WITH (METH)ACRYLOYL HALIDE | TOKUYAMA CORPORATION (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20030120106-A1 | Reacting a solution of a lithium 2-alkyl-2-adamantyl alcoholate to a (meth)acryloyl halide to produce 2-alkyl-2-admantyl (meth)acrylate | TOKUYAMA CORPORATION (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1283198-A1 | PROCESS FOR PRODUCING 2-ALKYL-2-ADAMANTYL ESTER | TOKUYAMA CORPORATION (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120106-A1 | Reacting a solution of a lithium 2-alkyl-2-adamantyl alcoholate to a (meth)acryloyl halide to produce 2-alkyl-2-admantyl (meth)acrylate | ADH1A, ADH5, ANO2 | CYP2C9 1461/4885EPHX2 3443/4885HSD11B1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.